Posted by Michael Wonder on 18 Oct 2018
Immusoft receives rare paediatric disease designation for treatment of MPS I
17 October 2018 - Company seeks to use engineered B cells to deliver missing enzyme for patients.
Immusoft Corporation announced today that the U.S. FDA has granted it rare paediatric disease designation for iduronicrin genleukocel-T, Immusoft’s Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alfa-L-iduronidase to treat mucopolysaccharidosis type I.
